Overview A Study of TG103 in Subjects With Type 2 Diabetes Status: Not yet recruiting Trial end date: 2022-03-01 Target enrollment: Participant gender: Summary The main purpose of this study is to assess the safety and tolerability of multiple ascending doses of TG103 in subjects with type 2 diabetes. Phase: Phase 1 Details Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.